Pfizer CEO says two Covid vaccine doses aren’t ‘enough for omicron’
Pfizer CEO Albert Bourla on Monday said two dosages of the organization's antibody may not give solid insurance against contamination from the omicron Covid variation, and the first shots have likewise lost a portion of their adequacy at forestalling hospitalization.
Bourla, in a meeting at J.P. Morgan's medical services gathering, accentuated the significance of a third shot to support individuals' assurance against omicron.
"The two dosages, they're insufficient for omicron," Bourla said. "The third portion of the current antibody is giving very great security against passings, and nice insurance against hospitalizations."
Bourla said omicron is a more troublesome objective than past variations. Omicron, which has many transformations, can sidestep a portion of the security given by Pfizer's unique two shots.“We have seen with a second dose very clearly that the first thing that we lost was the protection against infections,” Bourla said. “But then two months later, what used to be very strong in hospitalization also went down. And I think this is what everybody’s worried about.”
Real-world data from the United Kingdom has found that two vaccine doses are 52% effective at preventing hospitalization 25 weeks after receiving the second shot, according to data from the U.K. Health Security Agency.
CNBC Health & Science
Read CNBC’s latest global coverage of the Covid pandemic:
Pfizer CEO says two Covid vaccine doses aren’t ‘enough for omicron’
Pfizer CEO says omicron vaccine will be ready in March
Moderna’s working with world health leaders on Covid booster that targets omicron for this fall
Covid hospitalizations surge in New York City, but fewer patients are in the ICU
Supreme Court to hear challenges to Biden vaccine mandates
Moderna CEO warns people may need fourth Covid shot as efficacy of boosters likely to decline over time
Two-doses of Pfizer or Moderna’s vaccines are only about 10% effective at preventing infection from omicron 20 weeks after the second dose, according to the U.K. data.
A booster dose, on the other hand, is up to 75% effective at preventing symptomatic infection and 88% effective at preventing hospitalization, according to the data.
However, Bourla said it’s unclear how long a booster dose will provide protection against Covid. The U.K. Health Security Agency also found that boosters are only 40% to 50% effective against infection 10 weeks after receiving the shot.
“The question mark, it is how long that protection lasts with the third dose,” Bourla said.
The U.S. Centers for Disease Control and Prevention is now recommending that some people with compromised immune systems receive four shots, three primary doses and one booster. Israel has rolled out fourth Pfizer doses for people over the age of 60. Israel found that fourth doses increase protective antibodies fivefold.
Bourla told CNBC earlier Monday that Pfizer will have a vaccine that specifically targets omicron ready in March, though he said it’s not clear whether it will be needed or not.
Bourla also told CNBC more tests need to be done to determine whether or not fourth doses are necessary.
